ketoconazole has been researched along with fedratinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanamaluru, V; Krishna, G; Ogasawara, K; Palmisano, M; Xu, C | 1 |
| Krishna, G; Surapaneni, S; Wu, F | 1 |
2 other study(ies) available for ketoconazole and fedratinib
| Article | Year |
|---|---|
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Topics: Adult; Area Under Curve; Cohort Studies; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Synergism; Healthy Volunteers; Humans; Janus Kinase 2; Ketoconazole; Male; Primary Myelofibrosis; Pyrrolidines; Sulfonamides; Treatment Outcome | 2020 |
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Topics: Area Under Curve; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Janus Kinase 2; Ketoconazole; Midazolam; Models, Biological; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |